Form 4: AbbVie Director Acquires Stock Equivalent Units

AbbVie Director Edward J. Rapp acquired 147 stock equivalent units, increasing his beneficial ownership to 28,498 units, as part of director fee compensation.

Summary

• Edward J. Rapp, a Director of AbbVie Inc., reported the acquisition of 147 stock equivalent units on December 31, 2025.
• The units were acquired at a price of $228.49 per unit.
• These units represent director fees credited to a grantor trust, which are generally paid in cash upon the director reaching age 65 or retiring from the board.
• The stock equivalent units are designed to earn the same return as if the fees were invested directly in AbbVie common stock.
• Following this transaction, Rapp beneficially owns a total of 28,498 stock equivalent units.
• This total balance includes additional units acquired through a dividend reinvestment feature.

Sentiment

Score: 6

Explanation: The acquisition of stock equivalent units by a director, even as part of compensation, generally indicates alignment with shareholder interests and confidence in the company's long-term performance.

Positives

• Director Edward J. Rapp increased his beneficial ownership in AbbVie Inc. by acquiring 147 stock equivalent units.
• The stock equivalent units align the director's interests with shareholders by mirroring the return of AbbVie common stock.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Industry Context

This Form 4 filing reports a routine insider transaction related to director compensation and does not provide information relevant to broader industry trends or competitive analysis.

Related Party Transactions

• Director fees credited to a stock equivalent unit account under a grantor trust for Edward J. Rapp, paid in cash generally at age 65 or upon retirement from the board.

Stakeholder Impact

• Shareholders: The acquisition of stock equivalent units by a director enhances the alignment of management's interests with those of the shareholders.

Key Dates

Keywords

AbbVie, ABBV, Form 4, insider transaction, director, stock equivalent units, beneficial ownership, executive compensation